Company intelligence / Profile preview
BigHat Biosciences
San Mateo, California, United Statesbighatbio.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
BigHat is advancing a next-generation ADC for GI cancers into the clinic in 2026. The company has both wholly-owned and partnered therapeutic programs focusing on indications with high unmet need[9].
- Therapeutic areas
- OncologyImmunologyNeurology
- Modalities
- Antibody therapeuticsAntibody-drug conjugates (ADCs)T-cell engagers (TCEs)
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
AbbVie (December 2023)Eli Lilly (April 2025)Synaffix/Lonza (November 2024)
Beyond the preview
Go deeper on BigHat Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BigHat Biosciences.